Navigation Links
Breast cancers behave differently before and after the age of 70

Berlin, Germany: Researchers in Belgium have discovered that increasing age affects the way breast cancer behaves. As women approach the age of 70, they become less likely to be diagnosed with aggressive tumours that have spread to the lymph nodes. But after 70, the cancer is increasingly likely to spread, particularly if the tumours are small.

Until now, there has been conflicting evidence on aging and lymph node involvement and this study is the first to show clearly how the link between the two changes before and after the age of 70.

Professor Hans Wildiers told the 6th European Breast Cancer Conference (EBCC-6) in Berlin today (Friday), that he suspects that women older than 70 have decreased immune defence mechanisms, which are less able to deal with tumours that are likely to metastasise to other sites in the body.

The effect of age of lymph node positivity is not straightforward. There seems to be a different effect between women aged up to 70 years and women older than 70. For the younger group of women, age appears to have a negative effect on lymph node status the older they become, the less likely the cancer is to have spread to the lymph nodes. For the older group of women (aged over 70), age appears to influence lymph node status in the opposite way the older they become, the more likely they are to have cancer cells in the lymph nodes if the tumour is small, said Prof Wildiers, who is adjunct head of clinic in the department of general medical oncology at the Multidisciplinary Breast Centre, University Hospitals Leuven, Belgium.

There is an interaction between age and tumour size, suggesting that, up to the age of 70, age mainly has a positive effect on lymph node status for older women with small tumours. A likely explanation is that breast tumours metastasise less frequently to lymph nodes with increasing age due to the decreased biological aggressiveness in these tumours. On the other hand, over the age of 70, if the tumours have the potential to metastasise to lymph nodes, this occurs more rapidly in smaller tumours and this might be related to decreased immune defence mechanisms in elderly patients.

Prof Wildiers and his colleagues investigated 2,227 women who had been treated for breast cancer between 2000 and 2006 at the University Hospitals Leuven. Then they compared the results with a separate database of over 11,000 breast cancer patients on the Eindhoven Cancer Registry.

They found that for women aged 70 or younger, increasing age was associated with a decreased prevalence of cancer spreading to the lymph nodes. The womens risk of having positive lymph nodes decreased by 13% for every decade they aged, up to age 70.

Once aged 70 and over, the odds of lymph node involvement doubled with every 10-year increase in age for women who had tumours that were no bigger than 15mm across. If the tumours were larger than 42-43 mm, then risk of lymph node involvement continued to decrease.

Prof Wildiers said: We know that the elderly have depressed immune defences, and, therefore, it is possible that these decreased defences are unable to prevent invasion of the lymph nodes by metastases in a subset of breast tumours in elderly women. Although breast cancer survival in older women appears to be similar to survival in the general population irrespective of disease status, it might well be that there is a balance in the elderly between, on the one hand, a less aggressive type of tumour, and, on the other hand, their decreased immunological defences.

He said the findings supported the idea that there are two types of tumour in elderly women: ones that are slow-growing and dont invade the lymph nodes even if the tumours are larger, and ones that are aggressive and metastasise very early to the lymph nodes. Women with slow-growing tumours might benefit from less aggressive treatment, while the smaller tumours in the women aged over 70 might need to be treated more aggressively.

Further research now needs to be conducted into the role the immune system plays in lymph node invasion, he concluded.


Contact: Emma Mason
ECCO-the European CanCer Organisation

Related biology news :

1. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
2. New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
3. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
4. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
5. Pregnant patients lose out in breast cancer treatment; a new approach is needed
6. Improving care and knowledge in translational research to fight breast cancer
7. Evidence now suggests eating soy foods in puberty protects against breast cancer
8. T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role
9. MU researcher links hormone replacement therapy to breast cancer
10. Gene variant increases breast cancer risk
11. High levels of estrogen associated with breast cancer recurrence
Post Your Comments:
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
(Date:10/27/2015)... NEW YORK , Oct. 27, 2015 ... the major issues of concern for various industry verticals ... This is due to the growing demand for secure ... practices in various ,sectors, such as hacking of bank ... concerns for electronic equipment such as PC,s, laptops, and ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... , Dec. 01, 2015 ... addition of the "2016 Europe Cell ... Innovative Technologies, Competitive Strategies, Opportunities for Suppliers--France, ... their offering. --> ) ... "2016 Europe Cell Surface Markers: Country Volume ...
(Date:12/1/2015)... , Dec. 1, 2015  Symic, a clinical-stage biotherapeutics ... extracellular matrix (ECM), today announced that it has secured ... the company,s pipeline, including its lead candidates SB-030 and ... includes the participation by all existing major investors, as ... the total capital raised by Symic to over $43 ...
(Date:12/1/2015)... December 1, 2015 ... the  "2016 U.K. Virology and Bacteriology Testing ... 100 Tests, Supplier Shares by Test, Innovative ... their offering.  --> ) ... U.K. Virology and Bacteriology Testing Market: Sales ...
(Date:11/30/2015)... CHICAGO , Dec. 1, 2015  An interventional radiology ... according to the preliminary results of a study being presented ... North America (RSNA). ... been done for decades by interventional radiologists as a way ... performing the procedure as a means of treating obesity is ...
Breaking Biology Technology: